14. Segment Reporting

12 Months Ended

Dec. 31, 2019

14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products. We have two reportable segments: Life Science and Clinical Diagnostics. These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1). Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories. The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters. Segments are expected to manage only assets completely under their control. Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment. Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2019, 2018, and 2017 and for the years then ended is as follows (in millions):



		Life Science			Clinical Diagnostics			Other Operations
Segment net sales	2019	$	885.9		$	1,412.0		$	13.8
	2018	861.7			1,411.8			15.9
	2017	785.2			1,360.8			14.2

Allocated interest expense	2019	$	7.4		$	15.9		$	0.1
	2018	7.2			16.7			0.1
	2017	7.0			14.9			—

Depreciation and amortization	2019	$	29.4		$	71.7		$	0.9
	2018	34.1			72.0			0.5
	2017	36.2			80.2			—

Segment profit (loss)	2019	$	72.1		$	148.5		$	(1.5	)
	2018	28.7			(145.7		)	0.2
	2017	(9.9		)	114.8			1.4

Segment assets	2019	$	496.1		$	1,075.8		$	9.2
	2018	450.2			949.0			5.9

Capital expenditures	2019	$	16.6		$	58.9		$	0.6
	2018	36.7			60.5			0.5

Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements).

Segment assets at December 31, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 16 to the consolidated financial statements).

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):




	Year Ended December 31,
	2019			2018			2017
Total segment profit (loss)	$	219.1		$	(116.8	)	$	106.3
Foreign currency exchange losses, net	(2.2		)	(2.9		)	(9.1		)
Net corporate operating, interest and other expense not allocated to segments	(12.9		)	(10.4		)	(10.1		)
Change in fair market value of equity securities	2,031.0			606.2			—
Other income (expense), net	26.1			36.6			10.7
Consolidated income before income taxes	$	2,261.1		$	512.7		$	97.8

The following reconciles total segment assets to consolidated total assets (in millions):



	December 31,
	2019		2018
Total segment assets	$	1,581.1	$	1,405.1
Cash and other current assets	1,233.5		1,047.2
Property, plant and equipment, net, and operating lease right-of-use
assets, excluding segment specific balances	66.8		79.9
Goodwill, net	264.1		219.8
Other long-term assets	4,863.4		2,859.1
Total assets	$	8,008.9	$	5,611.1

Other long-term assets at December 31, 2019 increased from December 31, 2018 balance due to increase in fair market value of equity securities (see Note 3 to the consolidated financial statements).

The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):



	Year Ended December 31,
	2019		2018		2017
Europe	$	770.3	$	792.0	$	758.5
Asia	505.0		495.5		461.3
United States	899.1		863.6		800.2
Other (primarily Canada and Latin America)	137.3		138.3		140.0
Total net sales	$	2,311.7	$	2,289.4	$	2,160.2

The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):



	December 31,
	2019		2018
Europe	$	198.3	$	129.1
Asia	51.5		20.7
United States	468.7		369.2
Other (primarily Canada and Latin America)	12.7		11.1
Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes	$	731.2	$	530.1

Prior year amounts have been adjusted to exclude Other investments.